Online Healthcare Convention
May 18, 2021
DATE & TIME
Japanese Company Pitch
July 14-15, 2021
5:00 - 6:30 PM PDT
B2B Meetings
Anytime after the pitch for the company you intend to meet
VENUE
Online (Zoom)
COST
FREE *Registration Required*
REGISTRATION DEADLINE
July 13, 2021 @ 5:00 PM PDT
REGISTRATION FORM
(Keynote & Pitch Session)
CONTACT
JETRO San Francisco
sfc-marketing@jetro.go.jp
OVERVIEW
JETRO invites Japanese corporate venture capital groups (“CVCs”) and new tech/business hunters to make a reverse pitch on the topic of healthcare to potential collaborators. It welcomes as attendees individual companies, venture capitalists, accelerators, incubators, and tech/ business partners from the US and other countries.
The program focuses on Digital Health, Health Devices/Materials, Drug Discovery, and Science Parks, among other topics, and brings together attendees for B2B meetings.
JETRO also invites keynotes speakers who will give attendees insights on how to enter the Japanese market, regulation-related aspects by FDA, and advanced research and development by Japanese and US institutions.
This event is free-of-charge but pre-registration is necessary for both the keynote speech / Japanese company pitch portion and the pre-arranged B2B meetings.
Registration for B2B Meetings: OPEN NOW
Please contact Japanese companies through the "E-mail" shown beside each company's information to request a meeting. You can contact them immediately after registering for the conference. You may schedule your meeting for the prearranged time after the companies' pitch session or for another date or time.
We will record the pitch sessions for those who cannot attend in real time, but you MUST be pre-registered in order to receive a link. The recording will be uploaded day of, so please schedule your B2B meeting for AFTER you intend to watch it. This will help you understand the company's specific goals before meeting 1-on-1.
AGENDA
DAY 1 |
|
5:00 - 6:30 PM |
Greetings Maeda Toru, Consul General of Japan in San Francisco |
Keynote Speeches
Transpacific Collaboration of Healthcare Business Between Japan and US |
|
Japanese Company Pitches TOPICS: Digital Health, Device and Materials |
|
6:30 - 8:10 PM |
Prearranged B2B Meetings Participants may apply for a meeting during this time or ask Japanese companies for other dates and times. Contact them through the "E-mail" shown on each company's information. |
|
|
DAY 2 |
|
5:00 - 6:30 PM |
Support for Startups by Japanese Governmental Organizations Japan External Trade Organization (JETRO) New Energy and Industrial Technology Development Organization (NEDO) |
Keynote Speeches
Toward Bio Digital Twin Creation Based on Causal Mechanisms
SynFini™ - An Automated Chemistry Platform |
|
Japanese Company Pitches TOPICS: Drug Discovery, Science Park |
|
6:30 - 8:10 PM |
Prearranged B2B Meetings Participants may apply for a meeting during this time or ask Japanese companies for other dates and times. Contact them through the "E-mail" shown on each company's information. |
DAY 1 |
|
GREETINGS |
|
|
MAEDA Toru
|
KEYNOTES |
|
|
Transpacific Collaboration of Healthcare Business Between Japan and US Fumiaki Ikeno, MD
Stanford Biodesign
|
|
Pathways to the U.S. Market for Innovative Medical Devices Kenneth J. Cavanaugh Jr., Ph.D. Deputy Director Office of Cardiovascular Devices Center for Devices and Radiological Health U.S. Food and Drug Administration
|
|
Moderator
Chairman, U.S.-Japan MedTech Frontiers Partner, Nichibei MedTech Advisors, LLC Principal, LeVaunt, LLC
|
JAPANESE COMPANIES' PITCH SESSIONS |
|
Digital Health |
|
Request B2B meeting: |
Nippon Life Insurance Company
Nippon Life has collaborated with a number of startups to support their expansion into Japan since entering Silicon Valley in 2016, and in 2020, launched a CVC to start investment activities. The total fund size is $150m, $50m will be invested in strategic VC partners and $100m will be invested in early stage InsureTech, Healthtech and Fintech startups.
In this seminar, we will give an overview of our activities and explain one of our focus areas, the healthcare business in Japan.
|
Request B2B meeting: |
Dai-ichi Life Holdings, Inc.
As lifestyles continue to diversify, Dai-ichi Life Group will “Protect and improve the well-being of all” to enable a desired lifestyle and way of living for each individual. We believe that in addition to conventional protection, it is essential to provide value that contributes to financial wealth, wellness and enhancing social connections.
|
Request B2B meeting: |
SOMPO Himawari Life Insurance Inc.
SOMPO Himawari Life aims to be a "Total health support enterprise" and provides new value through "Insurhealth," which combines the essential functions of insurance and healthcare. We provide our customers with innovative insurance products and health services in partnership with companies with superior technologies, helping them to lead healthy lives.
|
Device and Materials |
|
Request B2B meeting: |
TEIJIN PHARMA LIMITED
Teijin Pharma, is a health care subsidiary of the Japanese Conglomerate, Teijin Group. Teijin Pharma seeks opportunities to introduce non-invasive medical devices/digital solutions into home healthcare in Japan. Historically, Teijin Pharma has had a strong portfolio of technologies and services in the respiratory and sleep areas. We are trying to enhance our existing business and expand into other chronic disease areas, like behavioral-health, lifestyle diseases, rehab, especially if these technologies allow for more effectively treatment at home.
|
Request B2B meeting: |
Murata Manufacturing Co., Ltd.
“Murata developing advancements in components and solutions for the medical devices of tomorrow.”
|
Request B2B meeting: |
Mitsui Chemicals, Inc.
Mitsui Chemicals – keen in robotics, sensing technology and data management |
Request B2B meeting: |
Toray Industries, Inc.
Toray is one of the world's leading chemical and materials companies, with sales exceeding $22 Billion and over 45,000 employed around the globe in 26 countries.
|
DAY 2 |
|
|
Support for Startups by Japanese Governmental Organizations
Tak Yamashita
New Energy and Industrial Technology Development Organization (NEDO) |
KEYNOTES |
|
|
Toward Bio Digital Twin Creation Based on Causal Mechanisms Joe Alexander, Jr. M.D., Ph.D., F.A.C.C.
|
|
SynFini™ - An Automated Chemistry Platform Nathan Collins, Ph.D.
|
JAPANESE COMPANIES' PITCH SESSIONS |
|
Drug Discovery |
|
Request B2B meeting: |
Takeda Pharmaceutical Company Limited
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company. Neuroscience is a core therapeutic area for Takeda. Our focused diseases are age-related neurological disorders, hereditary neurological disorders, and neuromuscular disorders. We are committed to working in partnership with external experts who share our vision and possess the knowledge and scientific capabilities to make truly transformational medicines for the patients we serve. See Takeda Wishlist (see English at bottom of document).
|
Request B2B meeting: |
SEKISUI CHEMICAL CO., LTD
Sekisui Chemical is a world-wide chemical company having broad business portfolio in “Innovative Mobility”, “Advanced Lifeline”, “Residential” and “Life Science” fields, with honorably selected GLOBAL100 (Most Sustainable Corporations in the World) for four sequential years. Our participation of this JETRO event aims at business expansion in the Life Science industry expecting to find new business partners in the US. We will promote our state-of-art mass cell processing materials and technologies.
|
Request B2B meeting: |
Astellas Innovation Management LLC
Astellas Innovation Management (https://aim.astellas.com/en) plays an important role in identifying, evaluating and accessing early-stage innovations into Astellas through a number of partnerships and alliances with various external partners. Located in key Bio-Hubs in the Bay Area CA, Cambridge MA, Cambridge UK, as well as Tsukuba Japan, AIM has built and developed a strong network across academia and the healthcare sectors. These networks have led to successful partnerships that create win-win situations for Astellas and partners. We look forward to working with you.
|
Request B2B meeting: |
Taiho Ventures, LLC
Taiho Ventures, LLC is the corporate venture arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharmaceutical company focusing on oncology, allergy and immunology, and urology. With $300M under management, we are actively investing in early-stage private companies strategically relevant to Taiho Pharmaceutical. We consider company creation, spinouts and the option-type of investments as well as pure equity investments.
|
Science Park | |
Request B2B meeting: |
Shonan Health Innovation Park
Shonan Health Innovation Park (Shonan iPark) is a science park founded in April 2018 by Takeda Pharmaceutical Company. It convenes private and public sector organizations and academic institutions that widely range in terms of business type and scale. More than 2,000 workers from over 100 pharmaceutical, next-generation medicine, AI, venture capital, and government-related companies and organizations together form an ecosystem to accelerate health innovation. |
PRESENTED BY
Japan External Trade Organization (JETRO) San Francisco
SUPPORTED BY
US-Japan Medtech Frontiers, New Energy and Industrial Technology Development Organization, Japan Society of Northern California, Japanese Chamber of Commerce of Northern California